TCRX
Tscan Therapeutics Inc

839
Mkt Cap
$64.69M
Volume
438,277.00
52W High
$3.00
52W Low
$0.8824
PE Ratio
-1.02
TCRX Fundamentals
Price
$1.20
Prev Close
$1.14
Open
$1.18
50D MA
$1.16
Beta
1.18
Avg. Volume
705,523.91
EPS (Annual)
-$1.14
P/B
0.45
Rev/Employee
$14,515.46
Loading...
Loading...
News
all
press releases
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Recommendation of "Hold" from Brokerages
Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) have been given an average recommendation of "Hold" by the seven analysts that are presently covering the company, Marketbeat.com...
MarketBeat·7d ago
News Placeholder
More News
News Placeholder
TScan Therapeutics (NASDAQ:TCRX) Major Shareholder Acquires $67,950.00 in Stock
TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) major shareholder Lynx1 Capital Management Lp bought 75,500 shares of the company's stock in a transaction dated Monday, December 22nd. The...
MarketBeat·14d ago
News Placeholder
TScan Therapeutics (NASDAQ:TCRX) Major Shareholder Buys 75,500 Shares
TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) major shareholder Lynx1 Capital Management Lp acquired 75,500 shares of TScan Therapeutics stock in a transaction that occurred on Monday...
MarketBeat·15d ago
News Placeholder
TScan Therapeutics (NASDAQ:TCRX) Major Shareholder Lynx1 Capital Management Lp Acquires 80,069 Shares
TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) major shareholder Lynx1 Capital Management Lp purchased 80,069 shares of the company's stock in a transaction that occurred on Friday...
MarketBeat·15d ago
News Placeholder
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines PR Newswire...
PR Newswire·19d ago
News Placeholder
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Rating of "Hold" from Analysts
Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) have been assigned a consensus recommendation of "Hold" from the seven analysts that are covering the stock, Marketbeat.com reports...
MarketBeat·1mo ago
News Placeholder
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points PR Newswire VANCOUVER, BC, Dec...
PR Newswire·1mo ago
News Placeholder
Equities Analysts Issue Forecasts for TCRX FY2025 Earnings
TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Equities researchers at HC Wainwright raised their FY2025 EPS estimates for TScan Therapeutics in a research note issued on Thursday, November...
MarketBeat·2mo ago
News Placeholder
Wedbush Reduces Earnings Estimates for TScan Therapeutics
TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Investment analysts at Wedbush dropped their FY2025 EPS estimates for TScan Therapeutics in a research note issued to investors on Wednesday...
MarketBeat·2mo ago
News Placeholder
TScan Therapeutics (NASDAQ:TCRX) Downgraded by Morgan Stanley to "Equal Weight"
Morgan Stanley cut shares of TScan Therapeutics from an "overweight" rating to an "equal weight" rating in a research note on Friday...
MarketBeat·2mo ago
<
1
2
...
>

Latest TCRX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.